--- title: "Boundless Bio (BOLD) news: reverse split, offering and merger" url: "https://aibio.space/companies/boundless-bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BOLD reverse split, offering and merger news: Boundless Bio files S-4 for Serapha merger; partner later reports early SERP-01 data. Boundless Bio, Inc." --- BOLD Boundless Bio, Inc. NASDAQ · United States # Boundless Bio (BOLD) news BOLD reverse split, offering and merger news Mergers · 2026-10-08 ## [Boundless Bio files S-4 for Serapha merger; partner later reports early SERP-01 data](https://aibio.space/news/boundless-bio-files-s-4-serapha-merger-partner-later-reports-early/) Boundless Bio filed a Form S-4 on October 8, 2026 for its merger with private Serapha Bio. The filing estimates about 8.6737 Boundless shares for each Serapha share before a planned reverse split, and expects existing Boundless holders to own about 3.8% of the combined company. ## Latest Boundless Bio news 1. 2026-06-23 Distress [Boundless Bio signs merger agreement with Serapha Bio, cuts workforce by approximately 75%](https://aibio.space/news/boundless-bio-signs-merger-agreement-serapha-bio-cuts-workforce/) Boundless Bio agreed to an all-stock merger with privately held Serapha Bio and said it would cut about 75% of its workforce. After closing, Boundless holders would own about 3.69% of the combined company, and most of the early data behind the deal come from a trial in Shanghai. 2. 2025-05-23 Distress [Boundless Bio cuts about one-third of workforce, narrows pipeline, sees cash into 2028](https://aibio.space/news/boundless-bio-cuts-about-one-third-workforce-narrows-pipeline-sees/) Boundless Bio will drop current BBI-355 trial arms and test BBI-355 with BBI-825. The cut is expected to cost about $1.2 million. Cash and short-term investments were $138.3 million on March 31, 2025, with runway expected into the first half of 2028. 3. 2025-04-01 Financings [Boundless Bio files $400.0 million shelf and $14.5 million Jefferies stock program](https://aibio.space/news/boundless-bio-files-400-0-million-shelf-14-5-million-jefferies-stock/) Boundless Bio filed a Form S-3 on April 1, 2025 covering up to $400.0 million of securities. The same day it signed an at-the-market sales agreement with Jefferies LLC for up to $14.5 million of common stock, which can start only after the SEC declares the registration effective. ## Boundless Bio at a glance - **Ticker**: BOLD - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $72.6 million ### Related companies - [Aldeyra Therapeutics](https://aibio.space/companies/aldeyra-therapeutics/) NASDAQ: ALDX - [Relay Therapeutics](https://aibio.space/companies/relay-therapeutics/) NASDAQ: RLAY - [Calidi Biotherapeutics](https://aibio.space/companies/calidi-biotherapeutics/) AMEX: CLDI - [MetaVia](https://aibio.space/companies/metavia/) NASDAQ: MTVA - [Tyra Biosciences](https://aibio.space/companies/tyra-biosciences/) NASDAQ: TYRA - [SpyGlass Pharma](https://aibio.space/companies/spyglass-pharma/) NASDAQ: SGP - [InVitro International](https://aibio.space/companies/invitro-international/) OTC: IVRO - [C4 Therapeutics](https://aibio.space/companies/c4-therapeutics/) NASDAQ: CCCC ### Also on NASDAQ - [Protara Therapeutics](https://aibio.space/companies/protara-therapeutics/) TARA - [Sonoma Pharmaceuticals](https://aibio.space/companies/sonoma-pharmaceuticals/) SNOA - [Immunic](https://aibio.space/companies/immunic/) IMUX - [Mangoceuticals](https://aibio.space/companies/mangoceuticals/) MGRX - [Sanara MedTech](https://aibio.space/companies/sanara-medtech/) SMTI - [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) IAM ## Boundless Bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$44.8 million](https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/) | [$55.3 million](https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/) | | Net income (loss) | [-$58.2 million](https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/) | [-$65.4 million](https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/) | | Cash from operations | [-$46.7 million](https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/) | [-$60.8 million](https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/) | | Cash and equivalents | [$17.9 million](https://www.sec.gov/Archives/edgar/data/1782303/000119312526339093/) | [$26.6 million](https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/) | | Short-term investments | [$89.7 million](https://www.sec.gov/Archives/edgar/data/1782303/000119312526339093/) | [$125.5 million](https://www.sec.gov/Archives/edgar/data/1782303/000119312526097543/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $20.2 million, plus short-term investments of $52.4 million, $72.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Boundless Bio Did Boundless Bio do a reverse stock split? Our latest story on this, dated Oct 8, 2026: "Boundless Bio files S-4 for Serapha merger; partner later reports early SERP-01 data". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/boundless-bio-files-s-4-serapha-merger-partner-later-reports-early/). Has Boundless Bio raised money recently? Our latest story on this, dated Apr 1, 2025: "Boundless Bio files $400.0 million shelf and $14.5 million Jefferies stock program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/boundless-bio-files-400-0-million-shelf-14-5-million-jefferies-stock/). Is Boundless Bio involved in a merger or acquisition? Our latest story on this, dated Oct 8, 2026: "Boundless Bio files S-4 for Serapha merger; partner later reports early SERP-01 data". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/boundless-bio-files-s-4-serapha-merger-partner-later-reports-early/). What is the ticker symbol of Boundless Bio? Boundless Bio, Inc. trades under the ticker BOLD on NASDAQ. Where is Boundless Bio listed? Boundless Bio, Inc. is listed on NASDAQ. What is the SEC CIK of Boundless Bio? The SEC Central Index Key (CIK) for Boundless Bio, Inc. is 1782303. Its filings are on SEC EDGAR. How many shares does Boundless Bio have outstanding? 22,747,985 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-07. Which country or territory is Boundless Bio listed under? Our directory records Boundless Bio, Inc. under United States. What does Boundless Bio do? Our directory classifies Boundless Bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Boundless Bio? The ISIN recorded for Boundless Bio, Inc. is US10170A1007. Does aibio.space cover Boundless Bio? aibio.space lists Boundless Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Boundless Bio incorporated? SEC records list its state or country of incorporation as DE. Is Boundless Bio profitable? Boundless Bio, Inc. reported a net loss of $58.2 million for the fiscal year ended Dec 31, 2025, and used $46.7 million of cash in operations, per its annual report to the SEC. How much does Boundless Bio spend on research and development? $44.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Boundless Bio have? $72.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Boundless Bio Members talk about Boundless Bio (BOLD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Boundless Bio, newest first. Each line links the filing it comes from. 1. 2026-10-08 Mergers Filed documents for a merger or acquisition. SEC Form S-4. [Source](https://www.sec.gov/Archives/edgar/data/1782303/000119312526417903/d108148ds4.htm) 2. 2026-06-23 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 1.01,2.05,3.02,5.01,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1782303/000119312526278570/d159021dex991.htm) 3. 2026-06-23 Mergers Reported a merger or acquisition agreement. SEC Form 425. [Source](https://www.sec.gov/Archives/edgar/data/1782303/000119312526278575/d159021d425.htm) 4. 2026-04-13 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,2.03). [Source](https://www.sec.gov/Archives/edgar/data/1782303/000119312526153076/bold-20260413.htm) 5. 2025-05-23 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1782303/000095017025076911/bold-20250523.htm) 6. 2025-04-01 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1782303/000119312525070393/d926309ds3.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BOLD on TradingView](https://www.tradingview.com/symbols/NASDAQ-BOLD/). ## SEC filings and registration - **SEC name**: Boundless Bio, Inc. - **CIK**: 1782303 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: BOLD (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company
Emerging growth company - **Business address**: 11099 NORTH TORREY PINES ROAD, LA JOLLA, CA, 92037 - **Phone**: (858) 766-9912 - **Shares outstanding**: 22,747,985 as of 2026-08-05 (10-Q filed 2026-08-07) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1782303/000119312526374787/d111273d8k.htm) filed 2026-08-28 - [10-Q](https://www.sec.gov/Archives/edgar/data/1782303/000119312526339093/bold-20260630.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1782303/000119312526278570/d159021d8k.htm) filed 2026-06-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1782303/000119312526273544/bold-20260615.htm) filed 2026-06-17 - [10-Q](https://www.sec.gov/Archives/edgar/data/1782303/000119312526213321/bold-20260331.htm) filed 2026-05-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1782303/000119312526213269/bold-20260508.htm) filed 2026-05-08 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1782303/000119312526186884/bold-20260428.htm) filed 2026-04-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1782303/000119312526153076/bold-20260413.htm) filed 2026-04-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001782303), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Boundless Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BOLD, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Boundless Bio, Inc. - **Ticker**: BOLD - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US10170A1007 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BOLD/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/boundless-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Boundless Bio (BOLD) news: reverse split, offering and merger", 2026-10-31, https://aibio.space/companies/boundless-bio/